Thank you for your interest in viewing the Update on ALS TDI Drug Development Pipeline webinar! Please join us on June 14, 2012 at 6:00 PM - 6:00 PM EDT
We will provide a comprehensive review of our current drug development pipeline, including the latest information on:
TDI 846 (Biogen Idec and UCB Pharma effort)
TDI 132 (clinical trial on Gilenya in ALS patients)
Regensance Partnership
Neurotune Partnership
Other partnerships
TDP43 mouse model charectorization
etc
Panelists include:
Steve Perrin, Ph.D.
John Lincecum, Ph.D.
Fernando G. Vieira, M.D.